X
Xianxian Zheng
Researcher at Pfizer
Publications - 15
Citations - 2037
Xianxian Zheng is an academic researcher from Pfizer. The author has contributed to research in topics: Pharmacodynamics & Notch signaling pathway. The author has an hindex of 12, co-authored 15 publications receiving 1741 citations.
Papers
More filters
Journal Article
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
David W. Fry,Patricia J. Harvey,Paul R. Keller,William Elliott,Maryanne Meade,Erin Trachet,Mudher Albassam,Xianxian Zheng,Wilbur R. Leopold,Nancy Pryer,Peter L. Toogood +10 more
TL;DR: Results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net reduction in tumor burden in some tumors.
Journal ArticleDOI
A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014
Wells A. Messersmith,Geoffrey I. Shapiro,James M. Cleary,Antonio Jimeno,Arvind Dasari,Bo Huang,Naveed Shaik,Rossano Cesari,Xianxian Zheng,Jennifer M. Reynolds,Patricia A. English,Karen McLachlan,Kenneth A. Kern,Patricia LoRusso +13 more
TL;DR: In this paper, the maximum tolerated dose (MTD) for continuous oral administration of the γ-secretase inhibitor PF-03084014, determine the recommended phase II dose (RP2D), and evaluate safety and preliminary activity in patients with advanced solid tumors.
Journal ArticleDOI
PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Kai Wang,Qin Zhang,Danan Li,Keith A. Ching,Cathy Zhang,Xianxian Zheng,Mark Ozeck,Stephanie T. Shi,Xiaorong Li,Hui Wang,Paul A. Rejto,James G. Christensen,Peter Olson +12 more
TL;DR: This work suggests that Notch-altered breast cancer constitutes a bona fide oncogenic driver segment with the most common alteration being PEST domain mutations present in multiple Notch receptors.
Journal ArticleDOI
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
Giovanni Martinelli,Vivian G. Oehler,Cristina Papayannidis,Rachel Courtney,Naveed Shaik,Xiaoxi Zhang,Ashleigh O'Connell,Karen McLachlan,Xianxian Zheng,Jerald P. Radich,Michele Baccarani,Hagop M. Kantarjian,Wendy J. Levin,Jorge E. Cortes,Catriona Jamieson +14 more
TL;DR: The maximum tolerated dose and the recommended phase 2 dose of the selective Hedgehog antagonist PF-04449913 in myeloid malignancies are identified and are being tested in phase 2 studies in patients with myelodysplastic syndrome, acuteMyeloid leukaemia, and myelofibrosis.
Journal ArticleDOI
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Cristina Papayannidis,Daniel J. DeAngelo,Wendy Stock,Bo Huang,Mohammed Naveed Shaik,Rossano Cesari,Xianxian Zheng,Jennifer M. Reynolds,Patricia A. English,Mark Ozeck,Jon C. Aster,Frank C. Kuo,Donghui Huang,Paul D. Lira,Karen McLachlan,Kenneth A. Kern,Guillermo Garcia-Manero,Giovanni Martinelli +17 more
TL;DR: A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T- cell lymphoblastics lymphoma shows promising results.